This trial is comparing the effect of adding ipatasertib (a protein kinase B inhibitor) to standard immunotherapy (pembrolizumab) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck. Ipatasertib may stop the growth of tumor cells and may kill them. Pembrolizumab may help the body's immune system attack the cancer. Giving ipatasertib in combination with pembrolizumab may be more effective than pembrolizumab alone in improving some outcomes in patients with recurrent/metastatic squ
1 Primary · 6 Secondary · Reporting Duration: Baseline up to 1 year after the last patient is enrolled
Active Control
Experimental Treatment
48 Total Participants · 2 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: